Scholarlink

<p>Extramedullary disease (EMD) is an aggressive manifestation of multiple myeloma (MM) and is categorized into two distinct types: extramedullary-bone-related (EM-B) and extramedullary-extraosseous (EM-E). We aimed to investigate differences in the characteristics of disease and outcomes between these two types. This single-center, retrospective study included 132 patients with EMD who were diagnosed with MM between January 2010 and January 2020. Patients were divided into EM-B (n = 93) and EM-E (n = 39), and clinicopathological features and survival outcomes were analyzed. EMD was observed in 98 (74.2%) patients at initial diagnosis and in 34 (25.8%) during a relapse. EM-E was significantly associated with ≥ 2 involved sites, high bone marrow plasma cell percentage, high LDH and beta-2 microglobulin levels, anemia, and high-risk fluorescence in situ hybridization abnormalities compared to EM-B. Patients with EM-E had significantly shorter progression-free survival and overall survival than those with EM-B. Anemia, hypercalcemia, high LDH, EMD at relapse, ≥ 2 involved sites, and not receiving autologous stem cell transplantation were independent poor risk factors for survival. In conclusion, EMD is a heterogeneous entity, and this study demonstrated that patients with EM-E presented with different clinicopathological characteristics and had worse survival compared to those with EM-B.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Extramedullary disease in multiple myeloma at diagnosis and over the course of the disease

  • 期刊论文

  • 发表日期：

    2025年3月3日

查看全文
  • Murad Guliyev,
  • Ali Tunc,
  • Umut Yılmaz,
  • Selin Kucukyurt,
  • Deniz Ozmen,
  • Tugrul Elverdi,
  • Ahmet Emre Eskazan,
  • Muhlis Cem Ar,
  • Yıldız Aydın,
  • Ayse Salihoglu

摘要

Extramedullary disease (EMD) is an aggressive manifestation of multiple myeloma (MM) and is categorized into two distinct types: extramedullary-bone-related (EM-B) and extramedullary-extraosseous (EM-E). We aimed to investigate differences in the characteristics of disease and outcomes between these two types. This single-center, retrospective study included 132 patients with EMD who were diagnosed with MM between January 2010 and January 2020. Patients were divided into EM-B (n = 93) and EM-E (n = 39), and clinicopathological features and survival outcomes were analyzed. EMD was observed in 98 (74.2%) patients at initial diagnosis and in 34 (25.8%) during a relapse. EM-E was significantly associated with ≥ 2 involved sites, high bone marrow plasma cell percentage, high LDH and beta-2 microglobulin levels, anemia, and high-risk fluorescence in situ hybridization abnormalities compared to EM-B. Patients with EM-E had significantly shorter progression-free survival and overall survival than those with EM-B. Anemia, hypercalcemia, high LDH, EMD at relapse, ≥ 2 involved sites, and not receiving autologous stem cell transplantation were independent poor risk factors for survival. In conclusion, EMD is a heterogeneous entity, and this study demonstrated that patients with EM-E presented with different clinicopathological characteristics and had worse survival compared to those with EM-B.